Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):937-945. doi: 10.1051/medsci/2019225. Epub 2020 Jan 6.

[The revolution of immuno-oncology therapy: review of immune checkpoint inhibitors efficacy].

[Article in French; Abstract available in French from the publisher]

Author information

1
Service de dermatologie, CHU Lille, Lille, France.
2
Service de pneumologie et oncologie thoracique, CHU Lille, Lille, France.
3
Service de pneumologie et oncologie thoracique, CHU Lille, Lille, France - Université de Lille, Lille, France - Unité Inserm 1189 OncoThAI, Lille, France.
4
Service de dermatologie, CHU Lille, Lille, France - Université de Lille, Lille, France - Unité Inserm 1189 OncoThAI, Lille, France.

Abstract

in English, French

Immunotherapy represents a major paradigm shift, as the treatment no longer directly targets tumor cells, but the patient him/herself, in order to restore an effective anti-tumor immunity. This article illustrates the growing place of immune checkpoint inhibitors in the available therapeutic options, by focusing on two cancers with poor outcome: metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), against which Immune checkpoints inhibitors now occupy a central place. Many questions remain unresolved, such as the search for markers predicting a good response to treatment, which would allow the selection of responder patients. Numerous trials are in progress, evaluating the relevance of these new molecules at earlier stages of the disease (adjuvant and neoadjuvant strategies) and their place in combined strategies (associated with chemotherapy, targeted therapies, and other types of immunotherapy).

PMID:
31903897
DOI:
10.1051/medsci/2019225

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center